Reimagining Care for Neurodegenerative Diseases

We harness the power of software to build evidence-based, precision digital therapeutics for neurodegenerative diseases.

By combining best-in-class cognitive rehabilitation strategies and machine learning approaches, our digital therapeutic and monitoring tools empower patients, families and clinicians by helping to preserve cognition and independence.

Home banner
Home banner

Reimagining Care for Neurodegenerative Diseases

We harness the power of software to build evidence-based, precision digital therapeutics for neurodegenerative diseases.

By combining best-in-class cognitive rehabilitation strategies and machine learning approaches, our digital therapeutic and monitoring tools empower patients, families and clinicians by helping to preserve cognition and independence.

second-section-banner

Alzheimer's and MCI

- a huge clinical unmet need

Over 50 million people worldwide suffer from Alzheimer’s disease (AD) and an equal number show signs of mild cognitive impairment (MCI), a potential precursor of the disease. Additionally, 150 million people may have pre-clinical dementia due to genetic risks and silent neuropathological changes. Currently approved symptomatic therapies offer only modest cognitive benefits and drop-out rates due to perceived lack of efficacy remain high. Several investigational drugs are in the pipeline but their success remains uncertain. Growing evidence supports the importance of complementary non-pharmacologic therapies such as cognitive rehabilitation, multi-domain lifestyle intervention, and patient education/support.

Developing digital therapeutics for AD/MCI

At Neuroglee Therapeutics, we are developing an investigational prescription digital therapeutic (DTx) that can be used independently or in conjunction with a pharmacotherapy for treating neurodegenerative diseases. Unlike wellness apps, digital therapeutics are designed to be used under the supervision of a clinician and undergo regulatory review/clearance for treating a specific disease.

Our initial software product, NG-001, is intended for the symptomatic treatment of Alzheimer's disease/MCI. It aims to provide a more personalized and engaging experience than existing non-pharmacological solutions. Through NG-001, our software captures digital biomarkers and learns from user behavior to provide a more personalized experience, resulting in best-fit therapy that is tailored to meet patient needs.

Baseline Assessment

Using advanced artificial intelligence, NG-001 continuously tracks digital biomarkers and performs a baseline assessment.

Cognitive Intervention

Based on assessment data, NG-001 personalizes each patient’s therapy by automatically adjusting the therapeutic mobile-based intervention for best results.

Continuous Monitoring

NG-001 constantly monitors cognitive health, physiology and lifestyle biomarkers using advanced biosensors and intuitive digital tools.

Transforming the
treatment ecosystem

NG-001 features digital tools for patients, caregivers and clinicians for more streamlined, efficient collaboration on neurodegenerative disease management.

Besides improving patient health outcomes and quality of life, efficient digital therapeutics also reduces the caregiving burden, accelerates the development of effective drugs in the pipeline.

Patients

Patients engage with the NG-001 app on a daily basis to access therapies and treatment schedules according to their conditions.

Caregivers

Caregivers can interact with and guide patients through their therapies on their own dashboard. They can also check patient progress and responses.

Clinicians

Clinicians can oversee patient medication adherence and therapeutic responses. This allows them to accurately asses drug and treatment efficacy.

NG-001 supports the ecosystem of care
around neurodegenerative diseases

NG-001 supports the ecosystem of care around neurodegenerative diseases

Patients​

Can improve their recall and cognitive abilities

Can better adhere to medication and treatment schedules

Can receive external support

Can reduce uncertainty and manage emotions

how-it-works-image-2v4

Clinicians

Can track patient medication adherence and drug efficacy

Can adjust treatment and dosage

Can remotely monitor patient progress

Caregivers​

Can support patients through their therapies

Can remotely monitor patient progress

Can enjoy a better quality of life through simplified and more effective caregiving

The minds behind the science

A world-class founding team with vast experience in cognitive neuroscience, dementia clinical trials, wearables and artificial intelligence. 

Aniket

Aniket Singh Rajput

Founder & CEO

Specializing in Robotics and Cognitive Neuroscience, Aniket is the driving force behind Neuroglee's mission to treat the untreatable.

Micheal

Dr Michael D. Patterson

Principal Cognitive Scientist

Dr Michael has published highly-cited papers on cognitive enhancement and measurement. His expertise contributed to the development of Neuroglee's MOA.

Manish Verma

Head of Software Development

Manish leverages over 20 years of experience in software development and deployment to build Neuroglee's solution.

Bikram Aditya Gangwar

AI Solution Architect

With extensive experience in data analysis and machine learning, Bikram's insight has been crucial in Neuroglee's software development.

Piyush Pandya

Sr UI/UX Designer

Piyush leverages over eight years of design experience to create simplified, intuitive interfaces, making Neuroglee software more accessible.

Priyanka

Dr Priyanka Ebnezar

Digital Content Writer

Formerly an editor on India’s largest academic network of doctors, Dr Priyanka creates content that effectively unpacks the science behind Neuroglee.

Request for a FREE Quote

Lorem Ipsum is simply dummy text of the printing and typesetting has been the industry's standard dummy text.

In the media